The State of the Art: Pharmacogenomics, Multi-Omics, and Translational Barriers in Antipsychotic Therapy

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Pharmacogenomics is a crucial area in neuropsychopharmacology, offering a scientific foundation for precision medicine in treating psychiatric disorders, particularly schizophrenia spectrum disorders (SSD). Patients with SSD exhibit significant variability in their response to antipsychotic drugs, ranging from lack of efficacy to severe adverse drug reactions. This variability is largely due to genetic differences affecting drug metabolism (e.g., CYP450 enzymes such as CYP2D6 and CYP1A2) and drug targets (e.g., dopamine D2 and serotonin 2A receptors). For instance, an individual’s metabolizer status can dramatically alter drug concentrations, influencing both therapeutic effectiveness and the risk of side effects, such as weight gain and extrapyramidal symptoms. Recent advancements including multi-gene panels and multi-omics approaches (genomics, epigenomics, and metabolomics) are deepening our understanding of these complex drug responses. While promising case studies and clinical trial data highlight the predictive power of pharmacogenetics, its routine clinical integration faces substantial challenges. These include the need for standardized protocols, more robust real-world evidence, and improved omics literacy among healthcare providers. Overcoming these hurdles through collaborative efforts and technological advancements is essential to fully achieve the potential of pharmacogenomics in personalizing antipsychotic treatment, ultimately leading to improved patient outcomes and more effective mental healthcare.

This publication has 73 references indexed in Scilit: